Evolent Health Inc (EVH) Receives Average Recommendation of “Buy” from Analysts
Shares of Evolent Health Inc (NYSE:EVH) have received an average rating of “Buy” from the thirteen ratings firms that are currently covering the firm. One analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $27.88.
A number of equities research analysts have weighed in on EVH shares. Goldman Sachs Group Inc raised Evolent Health from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective on the stock in a report on Wednesday, March 8th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Evolent Health in a report on Thursday, April 13th. Zacks Investment Research lowered Evolent Health from a “hold” rating to a “sell” rating in a report on Wednesday, February 1st. Oppenheimer Holdings Inc. started coverage on Evolent Health in a report on Monday, March 13th. They issued an “outperform” rating and a $28.00 price objective on the stock. Finally, CIBC started coverage on Evolent Health in a report on Tuesday, March 14th. They issued an “outperform” rating on the stock.
In related news, insider Tpg Growth Ii Advisors, Inc. sold 3,081,760 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $24.30, for a total value of $74,886,768.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Upmc sold 2,333,333 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $24.30, for a total value of $56,699,991.90. Following the completion of the sale, the insider now directly owns 6,434,283 shares in the company, valued at approximately $156,353,076.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,086,969 shares of company stock worth $244,450,701. 8.85% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE increased its position in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares during the period. American International Group Inc. increased its position in shares of Evolent Health by 7.5% in the first quarter. American International Group Inc. now owns 9,403 shares of the technology company’s stock valued at $210,000 after buying an additional 653 shares during the period. White Pine Investment CO increased its position in shares of Evolent Health by 0.8% in the first quarter. White Pine Investment CO now owns 97,470 shares of the technology company’s stock valued at $2,174,000 after buying an additional 750 shares during the period. UBS Asset Management Americas Inc. increased its position in shares of Evolent Health by 5.6% in the third quarter. UBS Asset Management Americas Inc. now owns 15,000 shares of the technology company’s stock valued at $369,000 after buying an additional 800 shares during the period. Finally, Teachers Advisors LLC increased its position in shares of Evolent Health by 5.1% in the fourth quarter. Teachers Advisors LLC now owns 25,119 shares of the technology company’s stock valued at $372,000 after buying an additional 1,211 shares during the period. Institutional investors own 52.14% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Evolent Health Inc (EVH) Receives Average Recommendation of “Buy” from Analysts” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/05/27/evolent-health-inc-evh-receives-average-recommendation-of-buy-from-analysts.html.
Shares of Evolent Health (NYSE:EVH) traded down 1.67% during mid-day trading on Monday, hitting $23.50. The stock had a trading volume of 641,605 shares. The firm has a 50 day moving average price of $23.12 and a 200 day moving average price of $19.84. The firm’s market cap is $1.36 billion. Evolent Health has a 52-week low of $14.50 and a 52-week high of $26.84.
Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, May 9th. The technology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $104.38 million. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The business’s revenue was up 116.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.16) EPS. Equities analysts predict that Evolent Health will post ($0.41) EPS for the current year.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Stock Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related stocks with our FREE daily email newsletter.